Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))

Satoko Koga, Hideya Onishi, Shogo Masuda, Akiko Fujimura, Shu Ichimiya, Kazunori Nakayama, Akira Imaizumi, Kenichi Nishiyama, Masayuki Kojima, Kei Miyoshi, Katsuya Nakamura, Masayo Umebayashi, Takashi Morisaki, Masafumi Nakamurab

研究成果: ジャーナルへの寄稿コメント/討論査読

抄録

The authors regret that they missed the below corrections. Abstract: 1P 11th line / Result: 6P second line / Result: 8P first line/ Discussion: 11P second line “autocrine”→“autologous”. The authors would like to apologise for any inconvenience caused.

本文言語英語
論文番号101344
ジャーナルTranslational Oncology
17
DOI
出版ステータス出版済み - 3月 2022

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル